



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

March 10, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD / Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

March 10, 2004

Date

Steven L. Highlander

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/766,778 entitled "METHODS AND COMPOSITIONS OF A NOVEL SERINE PROTEASE INHIBITOR" – Gary Clayman et al.*
Our reference: UTSC:631USD1
Client reference: MDA99-059

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:631USD1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642

SLH/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Gary Clayman *et al.*

Serial No.: 10/766,778

Filed: January 28, 2004

For: METHODS AND COMPOSITIONS OF A
NOVEL SERINE PROTEASE INHIBITOR

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: UTSC:631USD1

CERTIFICATE OF MAILING
37 C.F.R 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to:, MS DD /Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 10, 2004

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:631USD1.

This application is a divisional application of Serial No. 09/653,464, filed August 31, 2000 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/653,464.

Applicants respectfully request that the listed documents be made of record in the present case.


Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 10, 2004



Form PTO-1449 (modified)

Atty. Docket No.

UTSC:631USD1

Serial No.

10/776,778

List of Patents and Publications for Applicant's
INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Applicant

Gary Clayman, Torahiko Nakashima and Paul Spring

Filing Date:

January 28, 2004

Group:

Unknown

U.S. Patent Documents
See Page 1

Foreign Patent Documents
See Page 1

Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,057,414	10/15/91	Stief <i>et al.</i>	435	13	7/1/88
	A2	5,602,253	2/11/97	Antonsson <i>et al.</i>	544	330	6/6/95
	A3	5,866,413	2/2/99	Sambrook <i>et al.</i>	435	320.1	11/25/97
	A4	5,925,553	7/20/99	Clark <i>et al.</i>	435	184	9/8/97
	A5	6,312,695	11/06/01	Reed and Wang	424	185.1	7/27/98

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	DE 19742725	4/1/99	Germany			No
	B2	WO 00/58459	10/5/00	PCT			
	B3	WO 00/61612	10/19/00	PCT			
	B4	WO 99/47674	9/23/99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Abts <i>et al.</i> , "Cloning and Characterization of Hurpin (Protease Inhibitor 13): A New Skin-specific, UV-repressible Serine Proteinase Inhibitor of the Ovalbumin Serpin Family," <i>J. Mol. Biol.</i> , 293:29-39, 1999.
	C2	Abts <i>et al.</i> , "Analysis of UVB-modulated gene expression in human keratinocytes by mRNA differential display polymerase chain reaction," <i>Photochemistry and Photobiology</i> , 66(3):363-367, 1997.
	C3	Bartuski <i>et al.</i> , "Cytoplasmic Antiporteinase 2 (P18) and Bomapin (PI10) Map to the Serpin Cluster at 18q21.3," <i>Genomics</i> , 43:321-328, 1997.
	C4	Dvorak, <i>New Tumors: Wounds That Do Not Heal</i> ," <i>Eng. Journ. of Med.</i> , 315:1650-1659, 1986.

25392480.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:631USD1	Serial No. 10/776,778
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Gary Clayman, Torahiko Nakashima and Paul Spring	
		Filing Date: January 28, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C5	Frank <i>et al.</i> , "Evidence That Loss of Chromosome 18q Is Associated with Tumor Progression," <i>Cancer Res.</i> , 57:824-827, 1997.
	C6	Jones <i>et al.</i> , "Frequent Loss of Heterozygosity on Chromosome Arm 18q in Squamous Cell Carcinomas," <i>Arch. Otolaryngol. Head and Neck</i> , 123:610-614, 1997.
	C7	Jonson <i>et al.</i> , "Molecular Analyses of the 15q and 18q SMAD genes in pancreatic cancer," <i>Genes, Chromosomes & Cancer</i> , 24(1):62-71, 1999.
	C8	Mignatti <i>et al.</i> , "Tumor invasion through the human amniotic membrane: requirement a proteinase cascade," <i>Cell</i> , 47:487-498, 1986.
	C9	Ossowski and Reich, "Antibodies to Plasminogen Activator Inhibit Human Tumor Metastasis," <i>Cell</i> , 35:611-619, 1983.
	C10	Potempa <i>et al.</i> , "The Serpin Superfamily of Proteinase Inhibitors: Structure, Function, and Regulation," <i>J. Biol. Chem.</i> , 269(23):15957-15960, 1994.
	C11	Remold-O'Donnell, "The ovalbumin family of serpin proteins," <i>FEBS Lett</i> , 315(2):105-108, 1993.
	C12	Schneider <i>et al.</i> , "A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene," <i>Proc. Natl. Acad. Sci. USA</i> , 92:3147-3151, 1995.
	C13	Spring <i>et al.</i> , "Identification and cDNA Cloning of <i>headpin</i> , a Novel Differentially Expressed Serpin That Maps to Chromosome 18q," <i>Biochem. And Biophys. Research Communications</i> , 264:299-304, 1999.
	C14	Suminami <i>et al.</i> , "Squamous Cell Carcinoma Antigen is a New Member of the Serine Protease Inhibitors," <i>Biochem. Biophys. Res. Commun.</i> 181(1):51-58, 1991.
	C15	Unkeless et al, "Secretion of Plasminogen Activator by Stimulated Macrophages," <i>J. Exp. Med.</i> 139:834-850, 1974.
	C16	Unkeless, "Mouse macrophage Fc receptors," <i>J. Reticuloendothelial Soc.</i> , 28(Supp):11s-16s, 1980.
	C17	Zou <i>et al.</i> , "Maspin, a Serpin with Tumor-Suppressing Activity in Human Mammary Epithelial Cells," <i>Science</i> , 263:526-529, 1994.

25392480.1

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.